Federated Hermes Inc. Sells 3,650 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

Federated Hermes Inc. lessened its stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 0.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 907,714 shares of the company’s stock after selling 3,650 shares during the period. Federated Hermes Inc. owned 0.61% of MiMedx Group worth $6,290,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Victory Capital Management Inc. increased its position in shares of MiMedx Group by 23.1% in the fourth quarter. Victory Capital Management Inc. now owns 14,916 shares of the company’s stock worth $131,000 after purchasing an additional 2,796 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in MiMedx Group by 5.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,134,213 shares of the company’s stock valued at $9,947,000 after buying an additional 57,704 shares during the period. Campbell & CO Investment Adviser LLC raised its position in shares of MiMedx Group by 26.9% in the 4th quarter. Campbell & CO Investment Adviser LLC now owns 261,604 shares of the company’s stock valued at $2,294,000 after buying an additional 55,435 shares in the last quarter. Cannell Capital LLC lifted its holdings in shares of MiMedx Group by 9.1% during the 4th quarter. Cannell Capital LLC now owns 2,480,969 shares of the company’s stock worth $21,758,000 after acquiring an additional 207,207 shares during the period. Finally, Optimist Retirement Group LLC bought a new stake in shares of MiMedx Group during the 4th quarter worth approximately $177,000. 79.15% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have commented on MDXG. StockNews.com upgraded shares of MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, September 4th. Cantor Fitzgerald reissued an “overweight” rating and set a $11.00 price target on shares of MiMedx Group in a report on Thursday, August 1st. Finally, Craig Hallum reduced their price objective on MiMedx Group from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $12.00.

MiMedx Group Stock Up 0.5 %

Shares of NASDAQ:MDXG opened at $6.18 on Thursday. MiMedx Group, Inc. has a 52-week low of $5.57 and a 52-week high of $9.27. The company has a market capitalization of $912.19 million, a PE ratio of 14.05 and a beta of 1.98. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.22 and a current ratio of 3.85. The company has a fifty day moving average of $6.71 and a 200-day moving average of $7.04.

MiMedx Group (NASDAQ:MDXG) last issued its earnings results on Wednesday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.08. The business had revenue of $87.21 million during the quarter, compared to analysts’ expectations of $88.44 million. MiMedx Group had a return on equity of 34.24% and a net margin of 23.63%. On average, equities analysts predict that MiMedx Group, Inc. will post 0.26 EPS for the current fiscal year.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.